FDA Drafts Guidance for Individualized Gene Therapies
The U.S. Food and Drug Administration has issued new draft guidance for highly individualized gene therapies targeting rare genetic diseases. The guidance proposes using a “plausible mechanism” framework, which may allow a well-supported biological rationale to substitute for traditional efficacy endpoints in regulatory submissions for certain ultra-rare conditions.
- This guidance specifically targets genome editing and RNA-based therapies like antisense oligonucleotides (ASOs), aiming to streamline development for conditions where traditional randomized controlled trials are not feasible due to extremely small patient populations. - The framework was first described by FDA Commissioner Marty Makary and CBER Director Vinay Prasad in a November 2025 New England Journal of Medicine article, signaling a shift in regulatory thinking for ultra-rare diseases. - A key provision allows for a single product application to include therapies targeting different mutations within the same gene, potentially evaluated using a master protocol in one trial. - The guidance outlines a structured pathway where a first-in-human study could potentially serve as the pivotal trial for approval, a significant departure from traditional multi-phase trial requirements. - To leverage this pathway, developers must identify the disease's root biological cause, demonstrate the therapy targets this mechanism, use well-characterized natural history data, and confirm successful target engagement. - This initiative is part of a broader FDA effort to increase regulatory flexibility for cell and gene therapies, including more adaptable Chemistry, Manufacturing, and Controls (CMC) requirements to accommodate the unique aspects of these treatments. - The public has a 60-day period to comment on the draft guidance, which was issued by the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER). - Industry experts anticipate this guidance will spur innovation, lower costs, and encourage more focus on individualized therapies, which has been a significant challenge due to the high cost and complexity of development for very small patient populations.
